Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901452 | 0.82 | RORC (0.34) | RORC | |
| SCHEMBL5901223 | 0.77 | LMNA (0.35) | RAB9AMEN1TSHRKMT2ANPSR1 | |
| SCHEMBL4664776 | 0.74 | EGFR (0.37) | RAB9AMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL27162875 | 0.73 | PTGES (0.39) | TP53SMN1; SMN2RORCPTGES | |
| SCHEMBL30046089 | 0.73 | PTGES (0.39) | TP53SMN1; SMN2RORCPTGES | |
| SCHEMBL30699273 | 0.73 | RAB9A (0.50) | RAB9AMEN1TSHRKMT2ANPSR1 | |
| SCHEMBL15112138 | 0.73 | RAB9A (0.50) | RAB9AMEN1TSHRKMT2ANPSR1 | |
| SCHEMBL5902028 | 0.71 | CYP3A4 (0.50) | RAB9ANPC1RORCPTGES | |
| SCHEMBL30047210 | 0.67 | PTGES (0.40) | RAB9AMEN1TSHRKMT2ANPSR1 | |
| SCHEMBL27163209 | 0.67 | PTGES (0.40) | RAB9AMEN1TSHRKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | RAB9A 2294/4885MEN1 2551/4885TSHR 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.